Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

LATEST
Haier Smart Home Sees Profit Drop as Revenue Grows
Trending in China: Can You Stop People Giving ‘Too Much’ Money to Their Favorite Live-Streamers?
Trending in China: Concerns Over Traditional Chinese Comedy ‘Selling Out’ In the Digital Age
ByteDance Doubles Down On Education
Chinese Biotech Firm Gracell Nets $100m From Wellington, OrbiMed, Others
Alibaba’s Hometown Could Become First in China to Issue Facial Recognition Ban
Battery and Hybrid Cars Will Dominate China’s Roads in 15 Years
Trending in China: Do The Sins Of The Father Fall On Their Sons? Social Media Lambast Pop Star with ‘Deadbeat’ Dad
Chinese Electronics Panel Maker CSOT Reports Profit Growth as Demand Soars
Xiaomi Invests in Home Improvement Firm Amid Push into Internet of Things
TikTok Escalates Patent Fight With Triller Amid Sale Talks
Chinese Self-Heating Hot Pot Brand Zihaiguo Nets Over $50m in Series C Round Led by CICC
Xiaomi Leads India’s Smartphone Market with 26.1% Share
Trending in China: Are China’s Blue-Collar Wages Really Higher Than Graduate Salaries?
Trending in China: An End to Spam Calls? Real Estate Company to Give Money to Anyone Who Receives One
Trending in China: Patriotic War Film Overpowers Foreign-Made Feature, But Not Everyone Is Impressed
Shopify Partners with TikTok to Drive Online Sales
Lawson Tests Next Step of Convenience Store Evolution in China
PUBG Creator Krafton Hires Bankers for Possible Record IPO
Mobile Browser Crackdown Ensnares Big Names
Chinese Biotech Firm EdiGene Nabs $67m From Sequoia, IDG, Others

By DealStreetAsia / Oct 14, 2020 01:16 PM / Finance

Chinese novel gene-editing platform EdiGene Inc has raised 450 million yuan ($67 million) in its Series B round funding led by Chinese healthcare industry focused private equity fund 3H Health, according to a company statement on October 13.

New investors who participated in the round include Sequoia Capital China, early stage life science investment firm Alwin Capital and Beijing-based Kunlun Fund. A slew of existing investors also joined the fresh fundraising – including IDG Capital, Lilly Asia Ventures (LAV), Green Pine Capital Partners and Huagai Capital.

EdiGene will use the funding to advance its pipeline candidates into clinics and to expand its team.

With over 100 professionals globally, EdiGene specializes in leveraging new-generation genome editing technologies for drugs and therapies that cater to genetic diseases and cancers. Founded in 2015, the company has built four proprietary platforms such as high-throughput genome-editing screening and in vivo therapeutic platform to facilitate pipeline candidates entering into clinical trials.

The company is based in Beijing, and it has also set up a GMP and application center in Guangzhou, as well as a business development base in Cambridge, MA, U.S.

Per its recent press release in May, EdiGene has forged a partnership with Immunochina to develop allogeneic CAR-T therapy for cancer.

“We have raised approximately RMB 700 million ($104 million) in the past two years,” said Dr. Dong Wei, CEO, EdiGene, in the statement, “The round enables us to further scale up and transform our pipeline into clinical-stage, which is also a big step forward in building a globally competitive gene-editing company.

” IDG is a long-term backer of EdiGene. In September 2019, it had, along with LAV, invested 81.50 million yuan ($12 million) in EdiGene’s pre-B2 round. Previously, it had teamed up with other venture capital firms such as U.S global firm WI Harper Group to participate in EdiGene’s pre-B+, pre-B and Series A rounds.

Contact editor Yang Ge (geyang@caixin.com)

Related: Jack Ma-Backed Biotech Firm Considers Hong Kong IPO


Share this article
Open WeChat and scan the QR code